Zymeworks Raises $350 Million Notes and Launches Ampreloxetine CVR

Zymeworks announced multiple material agreements tied to its merger closing, including a $350 million senior secured note financing and a Contingent Value Rights (CVR) Agreement linked to ampreloxetine. The notes, purchased by OCM IP Healthcare Portfolio and carrying an 8.25% fixed rate to December…